Christopher Prentiss
Vermögen: 1 Mio $ am 31.05.2026
Vermögen: 1 Mio $ am 31.05.2026
Christopher B. Prentiss is Chief Financial Officer & Director at scPharmaceuticals, Inc. since 2025.
Mr. Prentiss is Chief Financial & Accounting Officer at MannKind Corp.
since 2024.
Former roles include Chief Financial Officer at Adamas Pharmaceuticals LLC from 2019 to 2021, Vice President-Finance & Controller at InterMune, Inc. from 2013 to 2015, Controller at Dynavax Technologies Corp.
from 2012 to 2013, Senior Manager at KPMG LLP from 1997 to 2005, Controller at MannKind Corp., and Chief Financial Officer at ADARx Pharmaceuticals, Inc. Education includes an MBA from Indiana University and an undergraduate degree from Loyola Marymount University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MANNKIND CORPORATION 0,11 % | 23.03.2026 | 348.854 ( 0,11 % ) | 1 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| MANNKIND CORPORATION | Finanzdirektor/CFO | 22.04.2024 |
| SCPHARMACEUTICALS INC. | Finanzdirektor/CFO | 07.10.2025 |
| Unternehmen | Position | Ende |
|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 24.11.2021 |
| INTERMUNE INC | Comptroller/Controller/Auditor | 01.03.2015 |
| DYNAVAX TECHNOLOGIES CORPORATION | Comptroller/Controller/Auditor | 01.06.2013 |
KPMG LLP
KPMG LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, tax and advisory services | Corporate Officer/Principal | 01.07.2005 |
ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage pipeline that develops RNA medicines for diseases | Finanzdirektor/CFO | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 9 |
|---|---|
InterMune, Inc.
InterMune, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that researches and develops therapies in pulmonology & orphan fibrotic diseases | Health Technology |
Dynavax Technologies Corp.
Dynavax Technologies Corp. BiotechnologyHealth Technology Develops and commercializes novel products to prevent and treat infectious diseases | Health Technology |
MannKind Corp.
MannKind Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes therapeutic products | Health Technology |
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets therapeutics for neurological diseases | Health Technology |
KPMG LLP
KPMG LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, tax and advisory services | Commercial Services |
Indiana University
Indiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Loyola Marymount University
Loyola Marymount University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
scPharmaceuticals, Inc.
scPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products to the cardiovascular and infectious diseases | Health Technology |
ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage pipeline that develops RNA medicines for diseases | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen